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Limited data are available regarding whether computer-aided diagnosis (CAD) improves assessment of malignancy risk
in indeterminate pulmonary nodules (IPNs).

Background:

Purpose: To evaluate the effect of an artificial intelligence–based CAD tool on clinician IPN diagnostic performance and agreement
for both malignancy risk categories and management recommendations.

This was a retrospective multireader multicase study performed in June and July 2020 on chest CT studies of
IPNs. Readers used only CT imaging data and provided an estimate of malignancy risk and a management recommendation for
each case without and with CAD. The effect of CAD on average reader diagnostic performance was assessed using the ObuchowskiRockette and Dorfman-Berbaum-Metz method to calculate estimates of area under the receiver operating characteristic curve
(AUC), sensitivity, and specificity. Multirater Fleiss k statistics were used to measure interobserver agreement for malignancy risk
and management recommendations.

Materials and Methods:

Results: A total of 300 chest CT scans of IPNs with maximal diameters of 5–30 mm (50.0% malignant) were reviewed by 12
readers (six radiologists, six pulmonologists) (patient median age, 65 years; IQR, 59–71 years; 164 [55%] men). Readers’ average
AUC improved from 0.82 to 0.89 with CAD (P , .001). At malignancy risk thresholds of 5% and 65%, use of CAD improved
average sensitivity from 94.1% to 97.9% (P = .01) and from 52.6% to 63.1% (P , .001), respectively. Average reader specificity
improved from 37.4% to 42.3% (P = .03) and from 87.3% to 89.9% (P = .05), respectively. Reader interobserver agreement
improved with CAD for both the less than 5% (Fleiss k, 0.50 vs 0.71; P , .001) and more than 65% (Fleiss k, 0.54 vs 0.71;
P , .001) malignancy risk categories. Overall reader interobserver agreement for management recommendation categories
(no action, CT surveillance, diagnostic procedure) also improved with CAD (Fleiss k, 0.44 vs 0.52; P = .001).
Conclusion: Use of computer-aided diagnosis improved estimation of indeterminate pulmonary nodule malignancy risk on chest CT
scans and improved interobserver agreement for both risk stratification and management recommendations.
© RSNA, 2022
Online supplemental material is available for this article.

I

ndeterminate pulmonary nodules (IPNs), rounded
opacities 3 cm or less in diameter surrounded by aerated
pulmonary parenchyma without clearly benign features,
pose a diagnostic challenge for clinicians (1,2). IPNs are
commonly identified on chest CT scans incidentally as
part of routine clinical care (3), and a growing proportion of IPNs are expected to be detected with lung cancer
screening (4–6).
As most IPNs are benign (2–5,7), it is critical for clinicians to accurately assess malignancy risk to both diagnose and treat malignant lesions in a timely fashion while
avoiding unnecessary tests and procedures in patients
with benign nodules (8). Guidelines from the American

College of Chest Physicians recommend CT surveillance
for lesions with very low risk (,5%) and functional imaging (ie, PET/CT) or nonsurgical biopsy for those with
low or moderate risk (range, 5%–65%). Surgical biopsy
can be considered in appropriately selected patients with
high-risk (.65%) lesions (1). However, prior studies have
demonstrated variable agreement among radiologists when
risk stratifying IPNs (9,10) and inconsistent adherence to
practice guidelines among pulmonologists (11). Moreover,
although several clinical risk prediction models have been
developed to estimate IPN malignancy risk (12–14), they
have not consistently outperformed physician assessment
of IPN risk (15–17).
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Abbreviations
AUC = area under the receiver operating characteristic curve, CAD =
computer-aided diagnosis, IPN = indeterminate pulmonary nodule,
LCP = lung cancer prediction, LCP-CNN = Lung Cancer Prediction
Convolutional Neural Network

Summary
An artificial intelligence–based computer-aided diagnosis tool
improved radiologists’ and pulmonologists’ risk stratification of indeterminate pulmonary nodules on chest CT scans.

Key Results
N

N

In this retrospective multireader multicase study with 300 chest
CT scans of pulmonary nodules and 12 readers (six pulmonologists, six radiologists), computer-aided diagnosis (CAD) improved
readers’ estimation of nodule malignancy risk (average area under
the receiver operating characteristic curve increased from 0.82 to
0.89, P , .001), regardless of reader specialty.
The average sensitivity and specificity of pulmonologists and
radiologists improved with CAD at both the very low (5%) and
high (65%) malignancy risk thresholds, suggesting that CAD
may have a meaningful impact on pulmonary nodule management decisions.

Recently, radiomics tools using raw CT data have been developed to help clinicians classify IPNs as malignant or benign
(18–20). The Lung Cancer Prediction Convolutional Neural
Network (LCP-CNN) is an artificial intelligence–based computer-aided diagnosis (CAD) model that was derived and internally validated using data from the National Lung Screening
Trial and externally validated in two cohorts of patients with incidentally detected IPNs (21,22). In these cohorts, malignancy
risk estimates provided by the LCP-CNN model had greater
discrimination than both the Brock and Mayo risk prediction
models (12,13,21,22). However, for CAD tools such as the
LCP-CNN to have practical clinical utility, they must provide
additional diagnostic benefit to clinicians interpreting chest CT
imaging results with IPNs.
Our main objective was to evaluate the effect of the LCP-CNN
CAD tool on the performance of radiologists and pulmonologists
in risk stratification of IPNs on chest CT scans. A prior pilot
study suggested a significant improvement in clinician IPN
discrimination with CAD (23). Here we report the results of a
larger multicenter validation study assessing the impact of LCPCNN CAD on clinicians’ risk stratification and management of
IPNs detected either incidentally or with lung cancer screening.

Materials and Methods
In this retrospective multireader multicase study, readers evaluated CT scans with and without the LCP-CNN CAD tool.
Deidentified imaging studies were collected from seven sources
with local institutional review board approval: two institutions
in the United States (Henry Ford Health System, Vanderbilt
University), four institutions in the United Kingdom (Royal
Berkshire Hospital, Leeds Teaching Hospital, Nottingham University Hospital, Oxford University Hospitals), and National
Lung Screening Trial data obtained through the National Cancer Institute Cancer Data Access System. The use of deidentified
imaging studies complied with Health Insurance Portability and
Accountability Act guidelines, and the need for informed con2

sent was waived. Evaluations by readers were conducted in June
and July 2020, and data analysis was performed from August
2020 to December 2021.
Authors who are not employees of or consultants for
Optellum (R.Y.K., J.L.O., A.V.) reviewed and analyzed the data.
One investigator (L.C.P.), who is an employee of Optellum,
helped curate the data and participated in study planning. One
author (F.V.G.) is a shareholder in Optellum and reviewed CT
scan data included in this study. The remaining authors have no
financial relationships with Optellum.
Calculation of the Lung Cancer Prediction Score
An artificial intelligence tool was used that evaluates raw CT
imaging data of an IPN of interest and calculates an estimated
probability of cancer (from 0 to 100). Methods for the development and validation of the LCP-CNN CAD software (Virtual
Nodule Clinic, version 2.0.0; Optellum) have been previously
described (21,22), and the product is commercially available.
These risk estimates are then converted to a lung cancer prediction (LCP) score that categorizes the malignancy risk on a decile
scale, with a score of 1 representing nodules at lowest risk and a
score of 10 indicating nodules at highest risk. In a target population with a malignant nodule prevalence of 30%, approximately
10% of all nodules (malignant and benign) will be categorized
within each decile of risk. The probabilities of a malignant nodule
within each decile are summarized in Figure 1. For this study, the
CAD software provided the LCP score and displayed Figure 1
to readers to allow the post-CAD risk determination.
Case Selection
The cases included in this study comprised imaging data from
both screening and diagnostic chest CT scans (Fig 2). No
imaging studies in the training data sets used for development of the LCP-CNN CAD were included in this study.
We selected the largest 5- to 30-mm IPN per chest CT scan,
and IPNs were defined as malignant or benign based on histologic evaluation. For cases without a definitive histologic
diagnosis, IPNs were determined to be benign if follow-up
imaging demonstrated complete resolution of the nodule or
2-year stability by nodule diameter.
We used a random weighted sampling approach to select
300 cases from the 5023 cases meeting inclusion criteria for
this study. The final data set was enriched to include a 50%
prevalence of malignancy, equitable distribution of case difficulty, and source of data (United States vs United Kingdom).
Representative axial images and corresponding LCP scores for
a malignant nodule and a benign nodule are shown in Figure
3. A detailed description of the selection algorithm is included
in Appendix E1 (online).
Readers and Reading Procedures
The 12 readers had current medical licenses and specialty certifications in radiology or pulmonary medicine. Each reader was
trained for 1 hour on the LCP-CNN CAD software and (21,22)
and evaluated 17 example cases before assessing images included
in the analysis. Readers were blinded to all patient clinical and
demographic information and were informed that the set of 300
radiology.rsna.org n Radiology: Volume 000: Number 0—Month 2022
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cases contained a higher prevalence of malignancy than in
routine clinical practice to provide modest guidance for malignancy risk assessments.
Readers began the interpretation of each of the randomly
ordered 300 cases by loading the
scan into the software, which
highlighted the IPN of interest,
and scrolling through the entire
set of images with axial views.
Readers estimated malignancy
risk on a 100-point scale and
separately selected a management recommendation from the
following six options: no action,
long-term (6 months) CT
follow-up, short-term (6 weeks
to 6 months) CT follow-up, immediate imaging follow-up (eg,
PET/CT), nonsurgical biopsy
(eg, needle biopsy), or surgical
resection. Immediately after this
initial assessment, the LCP score
was displayed, and readers were
asked to provide an updated risk
estimate and management recommendation (Fig E1 [online]).
Readers were not able to change
their initial malignancy risk estimate or management recommendation after seeing the LCP
score. Readers evaluated all cases
independently, and no reading
time limit was imposed.

Figure 1: The lung cancer prediction score is generated by an artificial intelligence tool and categorizes pulmonary
nodule malignancy risk on a decile scale, with a score of 1 representing nodules at lowest risk and a score of 10 indicating
nodules at highest risk.

Statistical Analyses
Power calculations were performed using estimates of the
relevant variances from the prior
pilot study (23) and implemented in the R software package RJafroc for the DorfmanBerbaum-Metz method. With
12 readers and 300 cases, the
study had 92% power to identify a minimum difference in
area under the receiver operating characteristic curve (AUC)
of 0.04 with use of CAD.
Figure 2: Flowchart shows inclusion and exclusion criteria for pulmonary nodules included in the study. IPNs = indetermiThe primary outcome was
nate pulmonary nodules.
the change in readers’ average
AUC between case malignancy
for all analyses of diagnostic performance in this study to test the
risk estimates with and without CAD. The Obuchowski-Rocknull hypothesis that the readers’ average AUC without CAD was
ette and Dorfman-Berbaum-Metz method for analyzing multiequal to that with CAD (25). The Obuchowski-Rockette and
reader multicase studies and the MRMCaov library (24) was used
Radiology: Volume 000: Number 0—Month 2022 n radiology.rsna.org
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Figure 3: Representative axial CT images of pulmonary nodules included in the study. (A) Malignant nodule
with a lung cancer prediction score of 10. (B) Benign nodule with a lung cancer prediction score of 2.

Table 1: Characteristics of Patients, Pulmonary Nodules, and Chest CT by Diagnosis

Variable
Age (y)†
Sex
Female
Male
Nodule diameter
5 to ,10 mm
10–30 mm
Nodule density
Solid
Mixed
Part solid
Nodule margins
Nonspiculated
Spiculated
Type of chest CT
Diagnostic
Screening
Reconstructed section thickness
0.5 to ,1.5 mm
1.5–2.5 mm

Total
(n = 300)
65 (59–71)

Benign IPNs
(n = 150)

Malignant
IPNs* (n = 150) P Value

62 (57–68)

68 (62–73)

136 (45)
164 (55)

55 (37)
95 (63)

81 (54)
69 (46)

120 (40)
180 (60)

84 (56)
66 (44)

36 (24)
114 (76)

,.001
.003
…
…
,.001
…
…
.003
…
…
…
,.001
…
…
,.001
…
…
.15
…
…

secondary analyses to compare the differences in average AUC stratified by
reader specialty, nodule size, density,
margins (spiculated vs nonspiculated),
and type of CT imaging (screening vs
diagnostic). We additionally calculated
the average sensitivity and specificity
across readers for IPN classification
with and without CAD at the 5% and
65% malignancy risk thresholds. Multirater Fleiss k statistics were used to
measure interobserver agreement for
IPN malignancy risk categories and
management recommendations with
and without CAD. The k values were
interpreted using Landis and Koch
guidelines (26).
Statistical significance was defined
with a two-sided P , .05, and no adjustments were made for multiplicity.
Analyses were performed using R software, version 4.04 (R Foundation) and
Stata/MP, version 17.0 (StataCorp),
and the code is available at https://
github.com/jokeyjo/Pulmonary-Nodules.

Results

Case and Reader Characteristics
Of the 300 chest CT scans each with
245 (82)
122 (81)
123 (82)
a single 5–30-mm IPN of interest, an
31 (10)
22 (15)
9 (6)
equal number (n = 150 [50.0%]) were
24 (8)
6 (4)
18 (12)
benign and malignant lesions (patient
median age, 65 years; IQR, 59–71
192 (64)
122 (81)
70 (47)
years; 164 [55%] men, 136 [45%]
108 (36)
28 (19)
80 (53)
women). Patient, pulmonary nodule,
and imaging study characteristics are
176 (59)
63 (42)
113 (75)
presented by IPN diagnosis in Table
124 (41)
87 (58)
37 (25)
1. Most IPNs (60.0% [180 of 300])
were 10 mm or greater in largest axial
194 (65)
91 (61)
103 (69)
diameter, and 81.7% (245 of 300)
106 (35)
59 (39)
47 (31)
and 64.0% (192 of 300) were solid
Note.—Unless otherwise indicated, data are number of patients, and data in parentheses are
and nonspiculated, respectively. Adpercentages. Mixed nodules were defined as those with cystic airspaces or pseudocavitation
enocarcinomas comprised 65.3% (98
or that were predominantly solid with a thin rim of ground-glass. Part-solid nodules had
of 150) of the malignant IPNs. Comground-glass and solid components. IPN = indeterminate pulmonary nodule.
pared with benign nodules, malignant
*Malignant histologic diagnoses included adenocarcinoma (98 of 150 [65.3%]), squamous
nodules were associated with older age
cell carcinoma (14 of 15 [93.3%]), other non–small cell lung cancer (27 of 150 [18.0%]),
small cell carcinoma (three of 150 [2.0%]), and other neoplasms (eight of 150 [5.3%]).
(median age, 68 years; IQR, 62–73
†
Data are median and data in parentheses are the interquartile range.
years] vs 62 years; IQR, 57–68 years;
P , .001), female sex (54% [n = 81]
vs 37% [n = 55], P = .003), part-solid
Dorfman-Berbaum-Metz method accounts for the fact that in a
density (12.0% [n = 18] vs 4.0% [n = 6], P = .003), increased
multireader multicase study, the same cases are evaluated by each
nodule diameter (median, 12.0 mm; IQR, 10.0–18.0 mm vs 8.5
reader. As such, error terms are assumed to be equi-covariant bemm; IQR, 6.0–13.0 mm; P , .001), and spiculation (53% [n =
tween readers and cases and are not assumed to be independent.
80] vs 19% [n = 28], P , .001). Figure E2 (online) displays the
We calculated 95% CIs using nonparametric bootstrap resamdistribution of LCP scores by diagnosis for the 300 cases. The 12
pling (n = 10 000) with the percentile method. We performed
readers included six pulmonologists (two with expertise in tho4
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racic oncology) and six radiologists (two with expertise in thoracic radiology) (Table E1 [online]). Tables E2 and E3 (online)
summarize reader estimates of malignancy risk and management
recommendations without and with CAD, respectively.
Diagnostic Performance
The average AUC across all readers for estimating malignancy
risk without CAD was 0.82 (95% CI: 0.77, 0.86) compared

Figure 4: Average reader receiver operating characteristic curves for discrimination of indeterminate pulmonary nodules under two reading conditions: without
computer-aided diagnosis (CAD) and with CAD. Average area under the receiver
operating characteristic curve (AUC) was computed across 12 readers participating in the study using either the Obuchowski-Rockette and Dorfman-BerbaumMetz method, which accounts for the multireader multicase study design.

with 0.89 (95% CI: 0.85, 0.92) with CAD (P , .001, Fig 4).
An improvement in AUC with CAD was observed for each of
the 12 readers (P  .001, Fig 5) and across prespecified strata
by reader specialty (pulmonology, P = .001; radiology, P =
.001), nodule diameter (5 to ,10 mm, P , .001; 10–30 mm,
P , .001), nodule density (solid or mixed, P , .001; part
solid, P = .05), nodule margins (nonspiculated, P , .001;
spiculated, P = .007), and type of chest CT (diagnostic, P
, .001; screening, P , .001; Table 2). We then evaluated
the effect of CAD on classification of IPNs by comparing
the average sensitivity and specificity of readers’ risk estimates with and without CAD at thresholds of 5% and 65%
(Table 3, Table E4 [online]). At the 5% threshold, the average sensitivity across readers was greater with CAD (1693 of
1800 [94.1%] vs 1762 of 1800 [97.9%], P = .01), as was
the average specificity (674 of 1800 [37.4%] vs 761 of 1800
[42.3%], P = .03). At the 65% threshold, the average sensitivity improved with CAD (946 of 1800 [52.6%] vs 1136
of 1800 [63.1%], P , .001), as did the specificity (1572 of
1800 [87.3%] vs 1619 of 1800 [89.9%], P = .05). Figure 6
and Table E5 (online) summarize the effect of CAD on reclassification of all IPN cases.
Interobserver Agreement
Overall agreement among readers for malignancy risk categories
improved with CAD (k = 0.35 vs k = 0.58, P , .001; Table
4). For very low malignancy risk (,5%), reader agreement
improved from moderate (k = 0.50) to substantial (k = 0.71)
with CAD (P , .001). Agreement among readers for high malignancy risk (.65%) similarly
improved from moderate (k =
0.54) to substantial (k = 0.71)
with CAD (P , .001). Improvements in agreement were
also observed in the 5%–30%
(k = 0.21 vs k = 0.45, P , .001)
and 31%–65% (k = 0.11 vs k =
0.36, P , .001) risk categories.
With CAD, there was improvement in agreement of
management recommendations (k = 0.44 vs k = 0.52,
P = .001). Reader agreement
(k) for management with diagnostic procedures improved
from 0.60 to 0.68 with CAD
(P = .008) and improved from
fair (k = 0.36) to moderate (k
= 0.43) for CT surveillance (P
= .02).

Discussion

Figure 5: Individual reader discrimination under two reading conditions: without computer-aided diagnosis (CAD) and
with CAD. There was a significant improvement in area under the receiver operating characteristic curve (AUC) for each
reader (P  .001) with CAD.
Radiology: Volume 000: Number 0—Month 2022 n radiology.rsna.org
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nodules (IPNs). In this multireader multicase study, the performance of radiologists and pulmonologists in estimation of
IPN malignancy risk significantly improved with the assistance
of an artificial intelligence–based CAD tool. The average area
under the receiver operating characteristic curve improved
from 0.82 to 0.89 (P , .001) with CAD, with an improvement observed for each of the 12 readers, regardless of clinician specialty. At the 5% and 65% malignancy risk thresholds,
use of CAD improved reader sensitivity from 94.1% to 97.9%
(P = .01) and from 52.6% to 63.1% (P , .001), respectively.
Specificity improved from 37.4% to 42.3% (P = .03) and from
87.3% to 89.9% (P = .05) at these thresholds, respectively.
Moreover, use of CAD improved the agreement among readers
for risk assessment (k = 0.35 vs k = 0.58, P , .001) and management recommendations (k = 0.44 vs k = 0.52, P = .001).
These results suggest that CAD may help clinicians more accu-

rately risk stratify pulmonary nodules when interpreting chest
CT imaging data.
Existing evidence on the management of IPNs suggests
considerable misalignment between malignancy risk and
subsequent management decisions, including a high rate of
benign diagnoses identified among patients undergoing invasive diagnostic procedures (15,27–29). This misalignment
exists at least in part because the two existing approaches
to IPN risk estimation—clinician-estimated risk and clinical risk prediction models—provide acceptable but far from
optimal discrimination in patients with IPNs (14–17,30).
Especially in intermediate-risk IPNs, this lack of precision
may contribute to instances in which malignant nodules are
managed with CT surveillance and benign nodules are managed with biopsy, resulting in delayed lung cancer diagnoses
and unnecessary procedural risks (27,31). The promise of
radiomics-based CAD tools
lies in the additional data inTable 2: Average AUC of Readers for Discrimination of Indeterminate Pulmonary Nodules
visible to the human eye (eg,
with and without CAD by Prespecified Subgroups
shape, spatial complexity,
textures, wavelet transformaAverage AUC
tions) provided to clinicians
Variable
Without CAD
With CAD
P Value
beyond IPN size, spiculation,
Reader specialty
and density—with the goal of
Pulmonology
0.82 (0.76, 0.87)
0.88 (0.85, 0.92)
.001
optimizing these challenging
Radiology
0.82 (0.77, 0.87)
0.89 (0.86, 0.93)
.001
diagnostic management deciNodule diameter
sions (32,33). Our findings
0.80 (0.74, 0.87)
0.91 (0.86, 0.96)
5 to ,10 mm
,.001
confirm that CAD can en0.77 (0.70, 0.83)
0.86 (0.80, 0.91)
,.001
10–30 mm
hance clinician interpretation
Nodule density
of risk based on imaging data
Solid or mixed
0.82 (0.78, 0.87)
0.88 (0.85, 0.92)
,.001
alone. Moreover, as the averPart solid
0.80 (0.63, 0.96)
0.94 (0.86, 1.00)
.05
age sensitivity and specificity
Nodule margins
of pulmonologists and radiNonspiculated
0.80 (0.74, 0.85)
0.88 (0.84, 0.93)
,.001
ologists improved with CAD
Spiculated
0.74 (0.64, 0.83)
0.81 (0.71, 0.90)
.007
at the very low (5%) and
Type of chest CT
high (65%) malignancy risk
Diagnostic
0.77 (0.70, 0.83)
0.84 (0.78, 0.90)
,.001
thresholds, CAD may have
Screening
0.85 (0.79, 0.92)
0.92 (0.87, 0.96)
,.001
a meaningful impact on pulNote.—Data in parentheses are 95% CIs. AUC = area under the receiver operating characteristic
monary nodule management
curve, CAD = computer-aided diagnosis.
decisions.
Table 3: Average Diagnostic Performance of Readers in Classification of Pulmonary Nodules with CAD

Malignancy Risk Threshold
5%

65%

Classification
Performance

Without CAD

With CAD

P Value

Without CAD

With CAD

P Value

True positive
False positive
True negative
False negative
Sensitivity (%)
Specificity (%)

1693
1126
674
107
94.1 (90.8, 97.4)
37.4 (27.2, 47.6)

1762
1039
761
38
97.9 (96.0, 99.7)
42.3 (31.3, 53.3)

…
…
…
…
.01
.03

946
228
1572
854
52.6 (41.8, 63.3)
87.3 (81.0, 93.6)

1136
181
1619
664
63.1 (53.7, 72.5)
89.9 (83.3, 96.6)

…
…
…
…
,.001
.05

Note.—Unless otherwise indicated, data are number of findings. Data in parentheses are 95% CI. Calculations were made using the
Obuchowski-Rockette and Dorfman-Berbaum-Metz method, which accounts for the multireader multicase study design. CAD =
computed-aided diagnosis.
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Figure 6: Reclassification plots with and without computer-aided diagnosis (CAD) for malignant and benign pulmonary nodules. Summary plots of all pairs of
pre-CAD (x-axis) and post-CAD (y-axis) malignancy risk estimates for malignant (n = 1800 [150 cases 3 12 readers]) (A) and benign (n = 1800 [150 cases 3 12
readers]) (B) nodules. Malignancy risk decision thresholds of 5% and 65% are depicted as gray lines in each plot.

Prior studies have demonstrated considerable variability among clinicians when classifying IPNs, which might
lead to differential management recommendations (9,10).
Thus, we sought to determine if reader agreement changed
with CAD. Agreement for both very low–risk and highrisk IPNs improved from moderate to substantial, suggesting that CAD may promote a more uniform approach to
IPN assessment. Although reader agreement also increased
in the intermediate-risk categories, it is unclear how this
might affect downstream clinical care, as there is considerably more variation in management strategies for nodules
with a malignancy risk of 5%–65%. That the overall reader
agreement for management recommendations was only
moderate in this study is consistent with prior studies demonstrating variable adherence to management guidelines
(10,11,15,27). Moreover, agreement may have been further
limited in this study because, by design, readers did not
have access to patient demographic or clinical information
when choosing management recommendations.
As our study included both screen-detected and incidentally detected IPNs, the results are generalizable to a broad
range of IPNs. Although prior similar studies have included
only experienced thoracic radiologists (19,20), the readers
in our study included both radiologists and pulmonologists
with a range of experience. Improvements in diagnostic performance with CAD did not differ by reader specialty, suggesting that CAD might benefit clinicians in a variety of
clinical settings.
Our study had limitations. First, readers were not provided
any clinical information when assessing IPN imaging data;
thus, generalizability to a routine clinical setting is limited.
Our intention was to avoid introducing bias and to exclude the
uncertainty of whether variability in image interpretation was
because of clinical context rather than nodule characteristics.
Radiology: Volume 000: Number 0—Month 2022 n radiology.rsna.org

Table 4: Interobserver Agreement for Malignancy Risk and
Management Recommendation with and without CAD

Interobserver Agreement
Variable
Malignancy risk
Very low (,5%)
Low-moderate
(5%–30%)
Moderate-high
(31%–65%)
High (.65%)
Overall
Management
recommendation
No action
CT surveillance*
Diagnostic
procedure†
Overall

Without CAD

With CAD

P Value

0.50 (0.45, 0.55) 0.71 (0.67, 0.75) ,.001
0.21 (0.18, 0.25) 0.45 (0.39, 0.50) ,.001
0.11 (0.09, 0.13) 0.36 (0.32, 0.41) ,.001
0.54 (0.49, 0.59) 0.71 (0.67, 0.76) ,.001
0.35 (0.32, 0.38) 0.58 (0.55, 0.61) ,.001

0.22 (0.18, 0.27) 0.32 (0.28, 0.36)
0.36 (0.32, 0.40) 0.43 (0.38, 0.47)
0.60 (0.55, 0.64) 0.68 (0.64, 0.72)

.002
.02
.008

0.44 (0.41, 0.48) 0.52 (0.49, 0.55)

.001

Note.—Unless otherwise indicated, data are Fleiss k statistics,
and data in parentheses are 95% CIs. k reported for each
separate category is calculated against all remaining categories
combined. The overall k is the weighted average of the individual
k statistics. CAD = computer-aided diagnosis.
* Short-term (6 weeks–6 months) or long-term ( 6 months)
chest CT follow-up.
†
Immediate imaging follow-up (eg, PET/CT scan), nonsurgical
biopsy (eg, needle biopsy), or surgical resection.

The LCP-CNN CAD tool estimates malignancy risk based on
imaging features without consideration of other clinical information (eg, age, smoking history), so our goal was to determine its impact on clinicians’ ability to evaluate IPNs in
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the absence of other risk factors. Second, before reviewing any
cases, readers were told that the prevalence of malignancy was
higher than is normally found in clinical practice, potentially
introducing context bias and inflating all risk estimates (34).
Third, the modest number of part-solid nodules included
in this study limits the generalizability of our results to this
subgroup of pulmonary nodules. Fourth, the LCP scores provided to readers were not accompanied by measures of uncertainty. Future studies should further evaluate the reliability of the LCP-CNN CAD tool. Fifth, although we observed
significant improvements in diagnostic performance for each
reader, the absolute increases in AUC across readers varied,
and additional work is necessary to quantify what constitutes a
clinically important improvement in discrimination. Sixth, as
with all CAD-based studies, our results are applicable only to
this software system, and other systems should not be assumed
to produce similar results.
In conclusion, our study found that an artificial intelligence–based computer-aided diagnosis (CAD) tool improved the performance of radiologists and pulmonologists
when estimating malignancy risk for indeterminate pulmonary nodules (IPNs) on chest CT scans and improved
agreement for very low- and high-risk IPN categories. Our
findings provide crucial support for bringing CAD tools
closer to clinical implementation for IPN risk stratification.
Furthermore, our results suggest that the Lung Cancer Prediction Convolutional Neural Network CAD tool may have
a meaningful impact on subsequent management decisions.
Future prospective studies will be necessary to evaluate the
effect of CAD on clinical and patient-centered outcomes in
real-world settings.
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